NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

NFJ Investment Group LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 278,792 shares of the biotechnology company’s stock, valued at approximately $2,788,000. NFJ Investment Group LLC owned about 0.11% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bank of America Corp DE raised its holdings in BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after acquiring an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $14,880,000. Wedge Capital Management L L P NC bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $3,808,000. Perceptive Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BCRX shares. Citizens Jmp lifted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Royal Bank Of Canada decreased their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Wedbush lowered their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $9.66 on Friday. The business has a 50 day simple moving average of $9.61 and a 200 day simple moving average of $8.93. The company has a market capitalization of $2.47 billion, a PE ratio of -6.44 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.